JX11502MA / Zhejiang Jingxin Pharma - LARVOL DELTA

Safety, tolerability, and pharmacokinetics of JX11502MA in Chinese healthy subjects: a first-in-human, randomized, double-blind, placebo-controlled study following single-dose administration. (PubMed, Expert Opin Investig Drugs) - P1 | "The PK profiles and safety characteristics in this study indicated that JX11502MA has the potential to be a favorable treatment option for patients with schizophrenia. https://clinicaltrials.gov (identifier: NCT05233657)."

Clinical • Journal • P1 data • PK/PD data • CNS Disorders • Psychiatry • Schizophrenia